JB Chem & Pharma
Ticker > Company >

JB Chem & Pharma share price

JB Chemicals & Pharmaceuticals Ltd.

NSE: JBCHEPHARM BSE: 506943 SECTOR: Pharmaceuticals & Drugs  1.2 L   435   75

1720.00
+1.15 (0.07%)
BSE: 08 Sep 04:01 PM

Price Summary

Today's High

₹ 1735

Today's Low

₹ 1709.15

52 Week High

₹ 1998

52 Week Low

₹ 1303

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 26949.24 Cr.

Enterprise Value

₹ 26858.67 Cr.

No. of Shares

15.67 Cr.

P/E

39.8

P/B

7.91

Face Value

₹ 1

Div. Yield

0.9 %

Book Value (TTM)

₹  217.46

CASH

₹ 90.57 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

47.73 %

EPS (TTM)

₹  43.22

Sales Growth

12.86%

ROE

21.91 %

ROCE

26.83%

Profit Growth

20.09 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of JB Chemicals & Pharmaceuticals Ltd.

Doktor Mom Metrogyl Rantac Nicardia Molunamax Azmarda Cilacar Sporlac Lobun Oxalo Pubergen Nano-leo Gynogen Akair LC Nintabid Viscojoy Cefjoy Tensimin Ifimol Motiza Dilcardia Nicardia Retard Daomet SR Nebilol Myotan Bisotab Azovas

Index Presence

The company is present in 22Indices.

NIFTYMNC

Nifty MNC
29987.15
  114.100000000002 (0.381949616795074%)

NFTSMLCAP250Q50

Nifty Smallcap250 Quality 50
26648.6
  5.44999999999709 (0.0204555392286476%)

NIFTY500

Nifty 500
22878.65
  49.5 (0.216828046598327%)

NIFTYPHARMA

Nifty Pharma
21865.2
  -59.5999999999985 (-0.271838283587533%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
19710.85
  61.5499999999993 (0.313242710936268%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
17594.05
  43.6499999999978 (0.24871228006198%)

NIFTYSMALLCAP250

Nifty Smallcap 250
16935.15
  30.9000000000015 (0.182794267713748%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
15947.85
  36.7000000000007 (0.230655860827156%)

NY500MUL50:30:20

Nifty500 Multicap India Manufacturing 50:30:20
15562.1
  188.85 (1.22843250451272%)

NFT500EQUAL

Nifty 500 Equal Weight
14242.5
  40 (0.281640556240093%)

NIFTYTOTALMCAP

Nifty Total Market index
12880.5
  28.9500000000007 (0.225264656792379%)

NIFTY500FLEXIQUAL30

Nifty500 Flexicap Quality 30 Index
10447.73
  -36.9899999999998 (-0.352799121006564%)

SMLCAP

S&P Bse Small Cap
52910.63
  158.32 (0.300119558745382%)

BSE HC

S&P Bse Healthcare
44127.07
  -126.970000000001 (-0.286911658235045%)

BSE500

S&P Bse 500
35916.19
  73.8500000000058 (0.206041235030985%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
11945.22
  39.369999999999 (0.330677776051269%)

BSE1000

Bse 1000
10706.29
  23.5900000000001 (0.22082432343884%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

SMLSEL

S&P Bse SmallCap Select Index
7900.98
  29.4499999999998 (0.37413311008152%)

SML250

S&P Bse 250 SmallCap
6775.32
  13.8299999999999 (0.204540715138224%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year12.86%
3 Year19.35%
5 Year17.81%

Profit Growth

1 Year20.09%
3 Year21.81%
5 Year19.47%

ROE%

1 Year21.91%
3 Year20.4%
5 Year21.49%

ROCE %

1 Year26.83%
3 Year24.66%
5 Year26.87%

Debt/Equity

0

Price to Cash Flow

30.48

Interest Cover Ratio

97.1971

CFO/PAT (5 Yr. Avg.)

1.16355659582823

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 47.73 0.00
Mar 2025 47.84 0.00
Dec 2024 53.66 0.00
Sep 2024 53.74 0.00
Jun 2024 53.77 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 21.8146851471329% for the Past 3 years.
  • The company has shown a good revenue growth of 19.3495110629789% for the Past 3 years.
  • The company has significantly decreased its debt by 341.7985 Cr.
  • Company has been maintaining healthy ROE of 20.3969% over the past 3 years.
  • Company has been maintaining healthy ROCE of 24.6616333333333% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 97.1971.
  • The Company has been maintaining an effective average operating margins of 25.2088262143182% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 5.47980000000001 days.
  • Company has a healthy liquidity position with current ratio of 2.0843.
  • The company has a good cash flow management; CFO/PAT stands at 1.16355659582823.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 952.31 955.76 913.51 901.34 1039.9
Total Expenditure 678.93 687.58 668.11 670.36 746.78
Operating Profit 273.38 268.18 245.4 230.98 293.12
Other Income 5.16 8.89 7.16 13.53 13.9
Interest 4.32 2.02 1.85 0.93 0.66
Depreciation 40.01 40.85 41.18 44.41 41.4
Exceptional Items 0 0 0 0 0
Profit Before Tax 234.21 234.2 209.53 199.17 264.96
Tax 60.98 61.08 53.14 49.37 67.09
Profit After Tax 173.23 173.12 156.39 149.8 197.87
Adjusted EPS (Rs) 11.16 11.15 10.06 9.62 12.68

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 1892 2189.88 2884.16 3298.64 3722.92
Total Expenditure 1339.66 1681.15 2219.47 2421.57 2707.65
Operating Profit 552.33 508.72 664.69 877.08 1015.27
Other Income 115.92 38.8 8.65 37.02 37.4
Interest 7.19 4.95 34.31 40.52 9.12
Depreciation 67.36 71.28 111.99 135.24 166.45
Exceptional Items 0 0 0 0 0
Profit Before Tax 593.71 471.29 527.04 738.34 877.11
Tax 146.62 110.29 138.15 194.98 224.56
Net Profit 447.08 361 388.89 543.36 652.54
Adjusted EPS (Rs.) 28.93 23.36 25.13 35.01 41.92

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 15.46 15.46 15.48 15.52 15.57
Total Reserves 1791 2088.21 2427 2870.74 3361.63
Borrowings 0 0 383.22 23.64 0
Other N/C liabilities 86.41 476.54 610.28 451.8 459.79
Current liabilities 645.74 418.54 579.28 1235.44 1101.4
Total Liabilities 2538.61 2998.75 4015.26 4597.14 4938.39
Assets
Net Block 564.6 1203.67 1821.66 1925.42 1883.29
Capital WIP 25.57 13.91 44.41 63.32 45.96
Intangible WIP 0 4.77 10.74 12.74 15.73
Investments 145.88 145.69 146.75 166.58 170.86
Loans & Advances 5.62 427.63 507.64 293.26 275.94
Other N/C Assets 0.82 1.04 14.51 6.03 250.98
Current Assets 1796.12 1202.05 1469.56 2129.78 2295.62
Total Assets 2538.61 2998.75 4015.26 4597.14 4938.39
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 593.71 471.29 527.04 738.34 877.11
Adjustment -56.41 97.05 202.82 187.26 194.07
Changes in Assets & Liabilities -61.45 -294.12 -12.62 -8.64 5.7
Tax Paid -140.41 -127.12 -88.59 -127.93 -192.84
Operating Cash Flow 335.43 147.1 628.64 789.03 884.03
Investing Cash Flow -230.64 4.18 -955.86 -412.47 -289.93
Financing Cash Flow -86.9 -137.85 343.41 -374.08 -574.27
Net Cash Flow 17.9 13.42 16.2 2.49 19.84

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 53.77 53.74 53.66 47.84 47.73
tau investment holdings p... 53.77 53.74 53.66 47.84 47.73
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 46.23 46.26 46.34 52.16 52.27
axis mutual fund trustee ... 2.83 2.81 3.16 3.29 3.01
canara robeco mutual fund... 1.12 1.26 1.53 1.91 1.98
franklin india smaller co... - - - 1.07 1.11
government pension fund g... 1.59 1.59 1.62 1.70 1.80
investor education and pr... - 0.36 - 0.37 0.37
kotak emerging equity sch... 1.53 1.64 2.83 4.25 4.35
nippon life india trustee... 2.98 2.99 2.67 2.30 2.35
smallcap world fund, inc - - - 1.05 1.05
tata aia life insurance c... - - - - 1.30
aberdeen standard sicav i... - - 1.04 1.10 -
investor education and pr... 0.36 - 0.38 - -
invesco india contra fund... 1.20 1.20 - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
Research BP Wealth
Research BP Wealth
Research BP Wealth
Research Monarch Networth Capital

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY22
Concall Q3FY24
Concall Q3FY23
Concall Q2FY24
Concall Q1FY25
Concall Q1FY24
Concall Q1FY22
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY23
Presentation Q4FY22
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY24
Presentation Q3FY22
Presentation Q2FY24
Presentation Q2FY22
Presentation Q1FY25
Presentation Q1FY24
Presentation Q1FY22

Company News

JB Chem & Pharma - Quaterly Results 30 Jul, 6:08 PM JB Chem & Pharma - Quaterly Results 30 Jul, 6:08 PM JB Chem & Pharma - Quaterly Results 30 Jul, 6:08 PM J. B. Chemicals & Pharmaceuticals gets USFDA’s nod for Amitriptyline Hydrochloride Tablets 25 Jun, 9:19 AM JB Chemicals & Pharmaceuticals informs about press release 18 Jun, 5:13 PM JB Chemicals & Pharmaceuticals informs about press release 15 May, 5:13 PM JB Chem & Pharma - Quaterly Results 14 May, 7:39 PM JB Chem & Pharma - Quaterly Results 14 May, 7:39 PM JB Chemicals & Pharmaceuticals informs about analyst meet 23 Apr, 3:57 PM J.B. Chemicals & Pharmaceuticals secures USFDA’s approval for Bisoprolol Tablets 21 Apr, 2:21 PM J.B. Chemicals & Pharmaceuticals informs about allotment of equity shares 18 Mar, 5:21 PM JB Chemicals & Pharmaceuticals informs about updates 15 Mar, 12:37 PM USFDA completes inspection of J.B. Chemicals’ formulations manufacturing facility in Gujarat 10 Mar, 10:58 AM J.B. Chemicals & Pharmaceuticals informs about allotment of equity shares 27 Feb, 5:10 PM J.B.Chemicals & Pharmaceuticals informs about disclosure 19 Feb, 5:18 PM J.B.Chemicals & Pharmaceuticals informs about outcome of analyst meet 5 Feb, 4:52 PM JB Chem & Pharma - Quaterly Results 4 Feb, 6:55 PM JB Chem & Pharma - Quaterly Results 4 Feb, 6:55 PM J.B. Chemicals & Pharmaceuticals informs about disclosure 16 Jan, 5:16 PM JB Chem & Pharma - Quaterly Results 6 Nov, 5:29 PM JB Chem & Pharma - Quaterly Results 6 Nov, 5:29 PM JB Chem & Pharma - Quaterly Results 6 Nov, 5:29 PM J.B.Chemicals & Pharmaceuticals informs about trading window closure 26 Sep, 5:32 PM J.B.Chemicals & Pharmaceuticals informs about analyst meet 3 Sep, 12:02 PM J.B. Chemicals & Pharmaceuticals informs about disclosure 29 Aug, 11:12 AM J.B. Chemicals & Pharmaceuticals informs about allotment of equity shares under ESOS 27 Aug, 10:44 AM JB Chem & Pharma - Quaterly Results 8 Aug, 5:06 PM JB Chem & Pharma - Quaterly Results 8 Aug, 5:06 PM JB Chem & Pharma - Quaterly Results 8 Aug, 5:06 PM J. B. Chemicals & Pharmaceuticals informs about newspaper advertisement 3 Jul, 5:25 PM J.B. Chemicals & Pharmaceuticals informs about transcript of conference call 24 May, 2:21 PM JB Chem & Pharma - Quaterly Results 17 May, 6:24 PM JB Chem & Pharma - Quaterly Results 17 May, 6:24 PM JB Chem & Pharma - Quaterly Results 6 Feb, 4:00 PM JB Chem & Pharma - Quaterly Results 6 Feb, 4:00 PM JB Chem & Pharma - Quaterly Results 6 Feb, 4:00 PM JB Chemicals & Pharmaceuticals to execute trade mark license agreement with Novartis Innovative Therapies AG 19 Dec, 2:43 PM J.B. Chemicals & Pharmaceuticals informs about allotment of equity shares under ESOS 30 Nov, 10:30 AM J.B. Chemicals & Pharmaceuticals informs about transcript of conference call 13 Nov, 5:18 PM JB Chem & Pharma - Quaterly Results 7 Nov, 3:29 PM JB Chem & Pharma - Quaterly Results 7 Nov, 3:29 PM JB Chem & Pharma - Quaterly Results 7 Nov, 3:29 PM J.B.Chemicals & Pharmaceuticals informs about trading window closure 27 Sep, 5:23 PM JB Chemicals & Pharmaceuticals gets USFDA’s nod for Doxepin Hydrochloride Capsules 23 Aug, 2:23 PM JB Chemicals gets nod to set up wholly-owned step-down subsidiary in Philippines 9 Aug, 5:20 PM JB Chem & Pharma - Quaterly Results 9 Aug, 3:43 PM JB Chem & Pharma - Quaterly Results 9 Aug, 3:43 PM JB Chem & Pharma - Quaterly Results 9 Aug, 3:43 PM JB Chemicals & Pharmaceuticals informs about details of loss of certificate 22 Jul, 12:47 PM USFDA completes inspection of J.B. Chemicals & Pharmaceuticals’ manufacturing facility at Gujarat 12 Jun, 2:50 PM

JB Chem & Pharma Stock Price Analysis and Quick Research Report. Is JB Chem & Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse JB Chem & Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). JB Chem & Pharma has a PE ratio of 39.9166128722516 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. JB Chem & Pharma has ROA of 13.6866% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. JB Chem & Pharma has a Current ratio of 2.0843.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. JB Chem & Pharma has a ROE of 21.9136%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. JB Chem & Pharma has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: JB Chem & Pharma has reported revenue growth of 12.8622% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of JB Chem & Pharma for the current financial year is 27.270750574616%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for JB Chem & Pharma is Rs 15.5 and the yield is 0.8997%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of JB Chem & Pharma is Rs 43.2201. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of JB Chem & Pharma in Ticker for free. Also, one can get the intrinsic value of JB Chem & Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

JB Chem & Pharma FAQs

Q1. What is JB Chem & Pharma share price today?
Ans: The current share price of JB Chem & Pharma is Rs 1725.2.

Q2. What is the market capitalisation of JB Chem & Pharma?
Ans: JB Chem & Pharma has a market capitalisation of Rs 27030.71463508 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of JB Chem & Pharma?
Ans: The PE ratio of JB Chem & Pharma is 39.9166128722516 and the P/B ratio of JB Chem & Pharma is 7.93355897284968, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of JB Chem & Pharma share?
Ans: The 52-week high share price of JB Chem & Pharma is Rs 1984, and the 52-week low share price of JB Chem & Pharma is Rs 1385.75.

Q5. Does JB Chem & Pharma pay dividends?
Ans: Currently, JB Chem & Pharma pays dividends. Dividend yield of JB Chem & Pharma is around 0.8997%.

Q6. What are the face value and book value of JB Chem & Pharma shares?
Ans: The face value of JB Chem & Pharma shares is Rs 1, while the book value per share of JB Chem & Pharma is around Rs 217.456. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of JB Chem & Pharma?
Ans: JB Chem & Pharma has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of JB Chem & Pharma?
Ans: The ROE of JB Chem & Pharma is 21.9136% and ROCE of JB Chem & Pharma is 26.8339%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is JB Chem & Pharma a good buy for the long term?
Ans: The JB Chem & Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is JB Chem & Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the JB Chem & Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check JB Chem & Pharma’s financials?
Ans: You can review JB Chem & Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about JB Chem & Pharma

JB Chemicals & Pharmaceuticals Ltd Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis 

 

Welcome to the stock analysis page for JB Chemicals & Pharmaceuticals Ltd, designed to provide in-depth analysis and insights for long-term stock investors. Explore various topics related to the company's performance and prospects to make informed investment decisions.

JB Chemicals & Pharmaceuticals Ltd Share Price 

Track and analyze the share price of JB Chemicals & Pharmaceuticals Ltd, a critical indicator for investors. Gain insights into the company's valuation and market sentiment using our pre-built screening tools.

JB Chemicals & Pharmaceuticals Ltd Balance Sheet 

Evaluate the financial stability and performance of JB Chemicals & Pharmaceuticals Ltd through its balance sheet analysis. Ticker offers valuable information, allowing you to understand the company's liquidity, solvency, and capital structure. Utilize our premium feature, BVPS Analysis, to calculate fair value based on the balance sheet.

JB Chemicals & Pharmaceuticals Ltd Annual Report 

Access the comprehensive annual report of JB Chemicals & Pharmaceuticals Ltd on Ticker. The annual report provides detailed information about the company's performance, strategic direction, and future plans. Download it from Ticker for a deeper understanding of the company's operations.

JB Chemicals & Pharmaceuticals Ltd Dividend 

Discover the dividend policy and track record of JB Chemicals & Pharmaceuticals Ltd, reflecting the company's commitment to rewarding shareholders. Our pre-built screening tools enable you to evaluate the company's dividend history and potential.

JB Chemicals & Pharmaceuticals Ltd Quarterly Results 

Stay updated on JB Chemicals & Pharmaceuticals Ltd quarterly performance through our detailed analysis. Our premium feature, Earnings Multiple Approach, helps assess the company's stock value based on its quarterly results.

JB Chemicals & Pharmaceuticals Ltd Stock Price 

Monitor the stock price of JB Chemicals & Pharmaceuticals Ltd to understand market sentiment and price movement. Our platform provides a comprehensive stock price chart for assessing historical performance and trends.

JB Chemicals & Pharmaceuticals Ltd Price Chart 

The price chart visually represents the historical performance of JB Chemicals & Pharmaceuticals Ltd stock. Analyze patterns, trends, and price levels to make well-informed investment decisions.

JB Chemicals & Pharmaceuticals Ltd News 

Stay up to date with the latest news articles about JB Chemicals & Pharmaceuticals Ltd through our dedicated news section. Timely information is crucial for investors, and Ticker ensures you are informed about the company's developments.

JB Chemicals & Pharmaceuticals Ltd Concall Transcripts 

Gain deeper insights into JB Chemicals & Pharmaceuticals Ltd's operations and plans by accessing transcripts of conference calls with analysts and investors. These transcripts provide valuable information about the company's strategies and future outlook.

JB Chemicals & Pharmaceuticals Ltd Investor Presentations 

View informative investor presentations of JB Chemicals & Pharmaceuticals Ltd, providing insights into the company's growth prospects and investment opportunities. Ticker offers access to these presentations, helping you understand the company's value proposition.

JB Chemicals & Pharmaceuticals Ltd Promoters & Shareholders 

Understand the ownership structure of JB Chemicals & Pharmaceuticals Ltd by learning about the key promoters and major shareholders. This information can help gauge ownership concentration and potential alignment of interests.

JB Chemicals & Pharmaceuticals Ltd ROCE

JB Chemicals & Pharmaceuticals Ltd's Return on Capital Employed (ROCE) is a key financial metric that evaluates the company's profitability and efficiency in utilizing its capital investments. Our stock analysis page provides the ROCE data for JB Chemicals & Pharmaceuticals Ltd, enabling investors to assess the company's ability to generate returns on the capital employed. By analyzing this ratio, investors can gain insights into the company's financial performance and make informed investment decisions. Access the detailed ROCE information for JB Chemicals & Pharmaceuticals Ltd in the financials table or ratio section on this page.

JB Chemicals & Pharmaceuticals Ltd EBITDA

JB Chemicals & Pharmaceuticals Ltd's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is a crucial measure for evaluating the company's operational performance and profitability. By analyzing the company's core earnings, investors can gain valuable insights into its financial health. Our stock analysis page offers comprehensive EBITDA data for JB Chemicals & Pharmaceuticals Ltd, enabling investors to assess the company's operational efficiency. Access the detailed EBITDA figures for JB Chemicals & Pharmaceuticals Ltd in the financials table or ratio section on this page.

JB Chemicals & Pharmaceuticals Ltd DPS

JB Chemicals & Pharmaceuticals Ltd's Dividends Per Share (DPS) signifies the portion of profits distributed to shareholders as dividends. Monitoring DPS is crucial for investors seeking a consistent income from dividends. Our stock analysis page features the DPS data for JB Chemicals & Pharmaceuticals Ltd, allowing investors to track the company's dividend history and payout ratio. Access the detailed DPS information for JB Chemicals & Pharmaceuticals Ltd in the financials table or ratio section on this page.

JB Chemicals & Pharmaceuticals Ltd EPS

Earnings Per Share (EPS) is an important financial metric that measures JB Chemicals & Pharmaceuticals Ltd's profitability on a per-share basis. By analyzing the company's EPS, investors can better understand its earnings performance and growth potential. Our stock analysis page provides detailed EPS information for JB Chemicals & Pharmaceuticals Ltd, enabling investors to assess the company's earnings trends and profitability. Access the comprehensive EPS figures for JB Chemicals & Pharmaceuticals Ltd in the financials table or ratio section on this page to make informed investment decisions. 

Brigade Enterprises Balance Sheet Analysis: Equity and Liabilities Trends

Brigade Enterprises Share Capital Growth

From March 2020 to March 2024, Brigade Enterprises has seen its share capital increase steadily from Rs 204.38 Cr to Rs 231.10 Cr. This indicates a gradual expansion in equity, supportive of potential growth strategies.

Brigade Enterprises Reserves Enhancement

There's a significant uplift in total reserves from Rs 2,339.15 Cr in March 2020 to Rs 3,989.23 Cr by March 2024. This robust escalation in reserves underscores the company's increasing internal strength and profitability.

Brigade Enterprises Debt Movements

The borrowings of Brigade Enterprises fluctuated, peaking at Rs 1,667.63 Cr by March 2024 up from Rs 1,510.54 Cr in March 2020. This reflects a renewed leveraging position that could affect the financial structure.

Brigade Enterprises Asset Management Insights

Brigade Enterprises Investment Strategies

Investments grew from Rs 1,776.60 Cr in March 2020 to Rs 2,496.70 Cr in March 2024, marking a focused strategy on asset growth through investments which could be pivotal for long-term asset returns.

Brigade Enterprises Operational Assets

Current assets evolved positively, rising from Rs 3,758.48 Cr to Rs 5,175.68 Cr during the observed period. This increase in current assets suggests better liquidity and operational capability, crucial for daily business operations.

This data represents an analysis of the standalone balance sheet of Brigade Enterprises.

Brigade Enterprises' financial indicators are an important tool for investors looking at market potential within the real estate sector.

 

Read More
X